Analysis shows cost-effectiveness of drug therapy for lymphatic filariasis in India, suggesting improved health resources.
We found that IDA is cost-effective, when compared with DA, offering better health outcomes and long-term cost savings. These findings support the adoption of IDA in Mass Drug Administration programs, promoting efficient resource use and advancing LF elimination goals by 2027.
No takes yet. Share an insight, caveat, or question.
Kaviya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: